Hence, we performed a meta-analysis to elucidate whether CD44 or CD133 overexpression would correlate with gastric cancer clinicopathology and prognosis and to explain which of these markers would have more clinical value based on the meta-analysis evidence. This evidence concerns the gene PROM1 and gastric cancer.